PALO ALTO, Calif., Jan. 21, 2025 /PRNewswire/ — Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, today announced that its Glooko XT solution has been approved for reimbursement by the Haute Autorité de Santé (HAS) and the Commission Nationale d’Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) in France. This decision, published in the French Journal Officiel (JO) on December 26, 20241, 2, allows healthcare providers to receive reimbursement for remote monitoring of gestational diabetes (GDM) in patients not treated with insulin.
This expands upon the existing reimbursement for Glooko XT for remote monitoring of people with insulin-treated diabetes, making it one of only two solutions in France with this GDM indication and further demonstrating the value of this technology in diabetes management.
GDM has a significant impact on maternal and fetal health in France:
Prevalence: GDM affects an estimated 8.8% of pregnancies
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
